HYAL3: A Potential Drug Target for Lung Cancer (G8372)

Target Name: HYAL3

NCBI ID: G8372

HYAL3

HYAL3: A Potential Drug Target for Lung Cancer

Hyal3, also known as Lung carcinoma protein 3, is a protein that is expressed in lung cancer cells. It is a glycoprotein that is characterized by its ability to bind to and stimulate the production of multiple cell surface antigens, including cancer antigens such as MHC class I and MHC class II molecules. This protein has been identified as a potential drug target for the treatment of lung cancer.

The Importance of HYAL3 in Lung Cancer

Hyal3 is a protein that is expressed in a wide range of tissues, including the lungs, and is known to play a role in the development and progression of lung cancer. It is expressed in high levels in lung cancer cells and has been shown to be involved in the development of both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

One of the key functions of HYAL3 is its ability to stimulate the production of multiple cell surface antigens, including cancer antigens such as MHC class I and MHC class II molecules. MHC class I and MHC class II molecules are proteins that are expressed in the immune system and play a critical role in presenting foreign particles, such as viruses and cancer cells, to the immune system for destruction. However, in cancer cells, MHC class I and MHC class II molecules can be mutated or expressed at high levels, leading to the cancer cells that evade the immune surveillance system and evade dysfunctional immune surveillance.

HYAL3 has been shown to play a role in the development of both SCLC and NSCLC. For example, studies have shown that high levels of HYAL3 are associated with poor prognosis in patients with NSCLC. Additionally, HYAL3 has been shown to be involved in the development of new biomarkers for the diagnosis and prognosis of NSCLC, such as the expression of HYAL3 has been shown to be associated with the poor prognosis in patients with NSCLC.

Drug Targeting of HYAL3

The potential drug targeting of HYAL3 makes it an attractive target for the treatment of lung cancer. One approach for targeting HYAL3 is to use small molecules that can inhibit its activity. One of the most promising small molecules is a drug called A312180, which is a small molecule inhibitor of the HYAL3 enzyme.

In clinical trials, A312180 has been shown to be effective in the treatment of NSCLC. Studies have shown that treatment with A312180 has led to a significant improvement in the treatment outcomes in patients with NSCLC, including a reduction in the size of tumors, improved breathing function, and increased survival times.

Another approach for targeting HYAL3 is to use antibodies that can specifically bind to and target the protein. One of the most promising antibodies is a monoclonal antibody (Mab) called GLT-1303, which is a humanized monoclonal antibody that can specifically bind to and inhibit the activity of HYAL3.

Studies have shown that GLT-1303 is effective in preclinical studies in treating NSCLC. GLT-1303 has been shown to reduce the size of NSCLC tumors, improve the treatment outcomes in animal models, and enhance the antitumor effect of chemotherapy in NSCLC models.

Conclusion

Hyal3 is a protein that is expressed in lung cancer cells and is involved in the development and progression of NSCLC. It is a potential drug target for the treatment of NSCLC, as it can stimulate the production of multiple cell surface antigens, including cancer antigens such as MHC class I and MHC class II molecules, and has been shown to play a role in the development of both SCLC and NSCLC. The potential drug targeting of HYAL3 makes it an attractive target for

Protein Name: Hyaluronidase 3

Functions: Facilitates sperm penetration into the layer of cumulus cells surrounding the egg by digesting hyaluronic acid. Involved in induction of the acrosome reaction in the sperm. Involved in follicular atresia, the breakdown of immature ovarian follicles that are not selected to ovulate. Induces ovarian granulosa cell apoptosis, possibly via apoptotic signaling pathway involving CASP8 and CASP3 activation, and poly(ADP-ribose) polymerase (PARP) cleavage. Has no hyaluronidase activity in embryonic fibroblasts in vitro. Has no hyaluronidase activity in granulosa cells in vitro

The "HYAL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HYAL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets